Oral anticoagulant treatment and risk of kidney disease—a nationwide, population-based cohort study

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Direct oral anticoagulants (DOACs) are recommended as first-line treatment of atrial fibrillation. Whether DOAC use is associated with lower risks of kidney complications compared with vitamin K antagonists (VKAs) remains unclear. We examined this association in a nationwide, population-based cohort study. Methods. We conducted a cohort study including patients initiating oral anticoagulant treatment within 3 months after an atrial fibrillation diagnosis in Denmark during 2012–18. Using routinely collected creatinine measurements from laboratory databases, we followed patients in an intention-to-treat approach for acute kidney injury (AKI) and chronic kidney disease (CKD) progression. We used propensity-score weighting to balance baseline confounders, computed weighted risks and weighted hazard ratios (HRs) with 95% confidence intervals (CIs) comparing DOACs with VKAs. We performed several subgroup analyses and a per-protocol analysis. Results. We included 32781 persons with atrial fibrillation initiating oral anticoagulation (77% initiating DOACs). The median age was 75 years, 25% had a baseline estimated glomerular filtration rate <60 mL/min/1.73 m2, and median follow-up was 2.3 (interquartile range 1.1–3.9) years. The weighted 1-year risks of AKI were 13.6% in DOAC users and 15.0% in VKA users (HR 0.86, 95% CI 0.82; 0.91). The weighted 5-year risks of CKD progression were 13.9% in DOAC users and 15.4% in VKA users (HR 0.85, 95% CI 0.79; 0.92). Results were similar across subgroups and in the per-protocol analysis. Conclusions. Initiation of DOACs was associated with a decreased risk of AKI and CKD progression compared with VKAs. Despite the potential limitations of observational studies, our findings support the need for increased clinical awareness to prevent kidney complications among patients who initiate oral anticoagulants.

References Powered by Scopus

A new equation to estimate glomerular filtration rate

20985Citations
N/AReaders
Get full text

Dabigatran versus warfarin in patients with atrial fibrillation

9828Citations
N/AReaders
Get full text

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

8210Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation

1Citations
N/AReaders
Get full text

Direct oral anticoagulants: the safer choice in chronic kidney disease?

1Citations
N/AReaders
Get full text

Anticoagulant-related nephropathy: a clinical risk to be vigilant

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Vestergaard, A. E. F., Jensen, S. K., Heide-Jørgensen, U., Adelborg, K., Birn, H., Carrero, J. J., & Christiansen, C. F. (2024). Oral anticoagulant treatment and risk of kidney disease—a nationwide, population-based cohort study. Clinical Kidney Journal, 17(1). https://doi.org/10.1093/ckj/sfad252

Readers over time

‘23‘24‘25036912

Readers' Seniority

Tooltip

Researcher 2

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

80%

Nursing and Health Professions 1

20%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0